​

Quince Therapeutics (QNCX) Stock Forecast, Price Target & Predictions

OverviewFinancialsChart

QNCX Stock Rating

Quince Therapeutics stock's rating consensus is Hold, based on 6 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 2 Buy (33.33%), 4 Hold (66.67%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Hold
Total 6 0 4 2 Strong Sell Sell Hold Buy Strong Buy

QNCX Price Target Upside V Benchmarks

TypeNameUpside
StockQuince Therapeutics-
SectorHealthcare Stocks 23.68%
IndustryBiotech Stocks 64.77%

Price Target Trends

1M3M12M
# Anlaysts---
Avg Price Target---
Last Closing Price$1.20$1.20$1.20
Upside/Downside---
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Jun, 2513---4
May, 2513---4
Apr, 2513---4
Mar, 2512---3
Feb, 2512---3
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Mar 24, 2025OppenheimerOutperforminitialise
Oct 29, 2024Rodman & RenshawBuyinitialise
Oct 22, 2024EF HuttonBuyinitialise

Financial Forecast

EPS Forecast

Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-0.84$-1.31----
Avg Forecast$-1.33$-1.22$-0.66$-0.63$-0.30$0.38
High Forecast$-1.33$-1.22$-0.66$-0.14$0.05$0.38
Low Forecast$-1.33$-1.22$-0.66$-1.06$-0.82$0.38
Surprise %-36.84%7.38%----

Revenue Forecast

$0 $50M $100M $150M $200M $250M Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported------
Avg Forecast----$48.91M$232.47M
High Forecast----$48.91M$232.47M
Low Forecast----$48.91M$232.47M
Surprise %------

Net Income Forecast

$-60M $-45M $-30M $-15M $0 $15M Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-31.39M$-56.83M----
Avg Forecast$-49.52M$-45.34M$-24.70M$-22.34M$-15.86M$14.03M
High Forecast$-49.52M$-45.34M$-24.70M$-5.21M$1.86M$14.03M
Low Forecast$-49.52M$-45.34M$-24.70M$-39.47M$-30.53M$14.03M
Surprise %-36.62%25.35%----

QNCX Forecast FAQ

Is Quince Therapeutics stock a buy?

Quince Therapeutics stock has a consensus rating of Hold, based on 6 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 2 Buy, 4 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Quince Therapeutics is a neutral investment for most analysts.

What is Quince Therapeutics's price target?

Quince Therapeutics's price target, set by 6 Wall Street analysts, averages - over the next 12 months. The price target range spans from - at the low end to - at the high end, suggesting a potential 0% change from the previous closing price of $1.2.

How does Quince Therapeutics stock forecast compare to its benchmarks?

Quince Therapeutics's stock forecast shows a 0% downside, underperforming the average forecast for the healthcare stocks sector (23.68%) and underperforming the biotech stocks industry (64.77%).

What is the breakdown of analyst ratings for Quince Therapeutics over the past three months?

  • June 2025: 25.00% Strong Buy, 75.00% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • May 2025: 25.00% Strong Buy, 75.00% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • April 2025: 25.00% Strong Buy, 75.00% Buy, 0% Hold, 0% Sell, 0% Strong Sell.

What is Quince Therapeutics’s EPS forecast?

Quince Therapeutics's average annual EPS forecast for its fiscal year ending in December 2025 is $-0.66, marking a -49.62% decrease from the reported $-1.31 in 2024. Estimates for the following years are $-0.63 in 2026, $-0.3 in 2027, and $0.38 in 2028.

What is Quince Therapeutics’s revenue forecast?

Quince Therapeutics's average annual revenue forecast for its fiscal year ending in December 2025 is $0, reflecting a 0% decrease from the reported $0 in 2024. The forecast for 2026 is $0, followed by $48.91M for 2027, and $232.47M for 2028.

What is Quince Therapeutics’s net income forecast?

Quince Therapeutics's net income forecast for the fiscal year ending in December 2025 stands at $-24.701M, representing a -56.53% decrease from the reported $-56.828M in 2024. Projections indicate $-22.342M in 2026, $-15.864M in 2027, and $14.03M in 2028.